Oral compounded versions use the same active ingredient but have not been studied in equivalent trials, and bioavailability may differ
Eur J Org Chem 2010:440445
Dosage Strength: The medications involve increased dosages (1200mg to 3000mg) that need sophisticated preparation and supervision with specialists which affect cost
The study was conducted in accordance with the Declaration of Helsinki and International Council for Harmonization (ICH) Good Clinical Practice guidelines
WischmeyerPERiehmJSingletonKDRenHMuschMWKahanaMet al
Metabolic rebound after GLP-1 reception agonist discontinuation This new meta-analysis compiled data from 18 studies (3771 participants) to establish the effects of discontinuing use of GLP-1 receptor agonists on metabolic outcomes Here are the main findings In adults with obesity, discontinuing GLP-1 receptor agonists use led to significant Weight regain (+5.63 kg) Increase in HbA1c (+0.25%) Plus increased waist circumference, BMI, systolic blood pressure and fasting plasma glucose In adults with diabetes, discontinuing GLP-1 receptor agonists use led to significant Weight regain (+2.03 kg) Increase in HbA1c (+0.65%) Weight regain was also greater with a longer follow-up period, indicating that weight regain continues to rise the longer the period of discontinuation This meta-analysis highlights key aspects of GLP-1 receptor agonist use: 1 GLP-1 receptor agonists use may only be a long term strategy to support weight loss (if you start, you stay using it) 2 You must combine GLP-1 receptor agonists use with behavioural interventions to support weight loss outcomes (diet and exercise) 3 You cannot rely of GLP-1 receptor agonists alone over the short term, and expect to maintain any metabolic and/or weight loss outcomes Reference: Subscribe to Performance Nutrition Digest FREE to receive your daily study breakdown, straight to your inbox or via the Substack app Performance Nutrition Digest is powered by Healthspan Elite GLP-1 Receptor Agonist Discontinuation Effects on Metabolism Metabolic rebound after GLP-1 reception agonist discontinuation This new meta-analysis compiled data from 18 studies (3771 participants) to establish the effects of discontinuing use of GLP-1 receptor agonists on metabolic outcomes Here are the main findings In adults with obesity, discontinuing GLP-1 receptor agonists use led to significant Weight regain (+5.63 kg) Increase in HbA1c (+0.25%) Plus increased waist circumference, BMI, systolic blood pressure and fasting plasma glucose In adults with diabetes, discontinuing GLP-1 receptor agonists use led to significant Weight regain (+2.03 kg) Increase in HbA1c (+0.65%) Weight regain was also greater with a longer follow-up period, indicating that weight regain continues to rise the longer the period of discontinuation This meta-analysis highlights key aspects of GLP-1 receptor agonist use: 1 GLP-1 receptor agonists use may only be a long term strategy to support weight loss (if you start, you stay using it) 2 You must combine GLP-1 receptor agonists use with behavioural interventions to support weight loss outcomes (diet and exercise) 3 You cannot rely of GLP-1 receptor agonists alone over the short term, and expect to maintain any metabolic and/or weight loss outcomes Reference: Subscribe to Performance Nutrition Digest FREE to receive your daily study breakdown, straight to your inbox or via the Substack app Performance Nutrition Digest is powered by Healthspan Elite To view or add a comment, sign in More Relevant Posts Vitamin B12 Deficiency Definition: Vitamin B12 deficiency is a condition caused by insufficient vitamin B12, leading to impaired DNA synthesis, megaloblastic anemia, and neurological dysfunction
